We've added 45 OCE clients this year, bringing our total number of clients to 125.
Revenue for the third quarter came in at $2,786 million, which was $11 million above the high end of our guidance range.
Third quarter adjusted EBITDA was $604 million with a $22 million beat versus the high end of our guidance range.
Third quarter adjusted diluted earnings per share was $1.63 reflecting the EBITDA drop-through because the below the line items essentially netted out to zero.
Third quarter R&DS contracted backlog, including pass-throughs, grew 18.5% year-over-year to $21.7 billion as of September 30th, 2020.
The contracted net book-to-bill ratio, including pass-throughs, was 1.71 for the third quarter of 2020 and 1.42 excluding pass-throughs.
The LTM contracted book-to-bill ratio at September 30 was 1.55, including pass-throughs and 1.45, excluding pass-throughs.
Third quarter revenue of $2,786 million grew 0.6% reported and was flat at constant currency.
Revenue for the first nine months of the year was $8,061 million which was down 1.6% reported and 1.2% at constant currency.
Technology & Analytics Solutions revenue of $1,207 million grew 10.2% reported and 9.2% at constant currency.
Year-to-date Tech & Analytics Solutions revenue was $3,433 million, up 4.9% reported and 5.6% at constant currency.
In R&D Solutions third quarter revenue of $1,400 million was down 4.5% at actual FX rate and 5.1% at constant currency.
Excluding the impact of pass-throughs, R&D Solutions third quarter revenue grew 2.6%.
Year-to-date revenue of $4,076 million was down 5.6% at actual FX rate and 5.4% at constant currency.
Contract Sales & Medical Solutions revenue of $179 million was down 13.9% year-over-year reported and 14.4% on a constant currency basis in the third quarter.
Year-to-date revenue was $552 million, down 8.6% at actual FX rates and 8.3% at constant currency.
Now moving down to P&L, adjusted EBITDA was $604 million for the third quarter, which represented growth of 1.9%.
Year-to-date adjusted EBITDA was $1,649 million.
Third quarter GAAP net income was $101 million and GAAP diluted earnings per share was $0.52.
Year-to-date GAAP net income was $160 million and GAAP diluted earnings per share was $0.82.
Adjusted net income was $318 million for the quarter and $841 million year-to-date.
Our adjusted diluted earnings per share grew 1.9% in the third quarter to $1.63.
Year-to-date adjusted diluted earnings per share was $4.32.
Consequent on the robust booking activity that Ari talked about, our backlog grew 18.5% year-over-year to close at $21.7 billion and we expect $5.8 billion of this backlog to convert to revenue over the next 12 months, which is an increase of over $400 million versus where we were at June 30th.
At September 30th, cash and cash equivalents totaled $1.5 billion and debt was $12.3 billion, resulting in net debt of $10.9 billion.
Due to our strong EBITDA and cash flow in the quarter, our net leverage ratio at September 30th was 4.7 times trailing 12-month adjusted EBITDA, which was down a tad [Phonetic] from where we were at June 30th.
Cash flow from operations was $574 million in the third quarter, up 74% over last year.
Capital expenditures were $157 million and that resulted in free cash flow of $417 million.
For the first nine months of the year, free cash flow was $769 million, which is about double the same period last year.
Underlying demand is robust and cash flow is as well and we have a very solid liquidity position closing the quarter with an undrawn revolver of almost -- undrawn revolver and almost $1.5 billion of cash in the balance sheet.
And as a reminder, we currently have about $1 billion of share repurchase authorization remaining under the program.
We now expect 2020 revenue for the full year to be between $11,100 million and $11,250 million, which is an increase of $125 million over our prior guidance at the midpoint of the range.
For profit we now expect full-year adjusted EBITDA to be between $2,335 million and $2,360 million, which represents a $27 million increase over our prior guidance at the midpoint of the range.
And adjusted diluted earnings per share, we are expecting to be between $6.25 and $6.35, which is an increase of $0.10 over our prior guidance at the midpoint of the range.
This full-year guidance implies fourth quarter revenue of $3,040 million to $3,190 million, representing growth of 5% to 10.2%.
For fourth quarter profit, we expect adjusted EBITDA to be between $685 million and $710 million, representing growth of 6.7% to 10.6% and adjusted diluted earnings per share to be between $1.93 and $2.03, or growth of 10.9% to 16.7%.
For the full year 2021, we expect revenue in the range of $12,300 million to $12,600 million.
This represents growth of 10.1% to 12.8% versus the midpoint of our 2020 guide.
We expect adjusted EBITDA to be in the range of $2,725 million to $2,800 million, representing growth of 16.1% to 19.3% compared to the midpoint of our 2020 guidance.
And finally, we expect adjusted earnings per share to be in the range of $7.65 to $7.95, which would represent growth of 21.4% to 26.2% compared to the midpoint of our 2020 guidance.
The adjusted diluted earnings per share guidance assumes interest expense of approximately $420 million, operational depreciation and amortization of about $400 million and other below the line expense items such as minority interest of approximately $50 million and also the continuation of our share repurchase activity.
